<DOC>
	<DOCNO>NCT00028769</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Androgens stimulate growth prostate cancer cell . Drugs goserelin , leuprolide , flutamide , bicalutamide may stop adrenal gland produce androgen . Combining chemotherapy hormone therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus hormone therapy treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>S0032 , Combination Chemotherapy Plus Hormone Therapy Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine progression-free overall survival patient high-risk metastatic adenocarcinoma prostate treat early estramustine , etoposide , paclitaxel combine androgen-blockade therapy . - Determine type , frequency , severity toxicity regimen patient population . OUTLINE : This multicenter study . - Androgen-blockade therapy : Patients receive standard regimen luteinizing hormone-releasing hormone agonist therapy comprise either goserelin subcutaneously monthly every 3 month leuprolide intramuscularly monthly , every 3 month , every 4 month . Patients also receive standard regimen antiandrogen therapy comprise oral bicalutamide , oral flutamide , oral nilutamide daily . Treatment continue absence disease progression unacceptable toxicity . - Chemotherapy : Beginning 14-30 day initiation androgen-blockade therapy , patient receive oral estramustine three time daily oral etoposide daily day 1-14 paclitaxel IV 1 hour day 2 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients follow every 3 month disease progression , every 6 month 2 year , annually 3 year . PROJECTED ACCRUAL : A total 80 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Nilutamide</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm highrisk adenocarcinoma prostate Clinical stage D2 disease evidence one following : Visceral disease ( liver , lung , viscera ) Bone metastases sit axial ( spine , pelvis , rib , skull ) appendicular ( claviculae , humerus , femur ) skeleton No prior concurrent ( treat untreated ) brain metastasis Patients clinical evidence brain metastasis must negative brain CT MRI No evidence untreated spinal cord compression PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 No active hypercoagulability Hepatic : Not specify Renal : Not specify Cardiovascular : No transient ischemic attack , stroke , myocardial infarction within past 6 month No active coronary artery disease require antianginal therapy No active thrombophlebitis Pulmonary : No history pulmonary embolus Other : No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer adequately treat stage I II cancer currently complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover No concurrent biologic therapy Chemotherapy : No prior cytotoxic chemotherapy No concurrent chemotherapy Endocrine therapy : Prior androgenblockade therapy ( e.g. , luteinizing hormonereleasing hormone agonist antiandrogen therapy ) allow administer duration less 30 day Prior neoadjuvant hormonal therapy allow Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : At least 4 week since prior surgery recover Other : No concurrent bisphosphonates</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>